ImClone Systems to Present at the Goldman Sachs 27th Annual Healthcare Conference.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- In first graph, first sentence of release, times in parentheses See parenthesis. parentheses - See left parenthesis, right parenthesis. should read: 4:40 PM to 5:15 PM Eastern Daylight Time (sted 10:40 AM to 11:15 AM Eastern Daylight Time). The corrected release reads: IMCLONE SYSTEMS TO PRESENT AT THE GOLDMAN SACHS 27TH ANNUAL HEALTHCARE CONFERENCE ImClone Systems Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : IMCL IMCL International Making Cities Livable IMCL Inter Marine Container Lines IMCL International Management Consultants Ltd. IMCL Indraprastha Medical Corp Ltd (India) IMCL Imperial Majesty Cruise Line ) announced today that Ronald A. Martell, Senior Vice President, Commercial Operations, is scheduled to present at the Goldman Sachs 27th Annual Healthcare Conference in Dana Point, CA on Wednesday, June 14, 2006, from 1:40 PM to 2:15 PM Pacific Daylight Time (4:40 PM to 5:15 PM Eastern Daylight Time). A Q&A session with the analyst and audience will follow a brief introduction by Mr. Martell. The presentation will be webcast live and may be accessed by visiting ImClone Systems' website at www.imclone.com. A replay of the webcast will also be available immediately after the conclusion of the presentation. Investors can access the webcast under "Presentations" in the "Investor Relations Investor relations The process by which the corporation communicates with its investors. " section of ImClone Systems' website. About ImClone Systems Incorporated ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , with additional administration and manufacturing facilities in Branchburg, New Jersey. Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission including quarterly reports on Form 10-Q Form 10-Q See 10-Q. , current reports on Form 8-K Form 8-K The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock. Form 8-K See 8-K. and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion